AGMB Stock — AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV American Depositary Shares (AGMB)

Updated October 16, 2026.

AGMB is a Stock. Total return is -48.3% over the past 0.7 years, 61.8 points behind SPY at 13.5%.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, with a pipeline including an oral treatment for fibrostenosing Crohn's disease in Phase 2a trials, an inhaled therapy for idiopathic pulmonary fibrosis in Phase 1 trials, and a monoclonal antibody candidate in preclinical development. As an early-stage biotech company with no approved products, it does not currently distribute to shareholders. This security appeals to investors with high risk tolerance seeking exposure to clinical-stage biopharmaceutical development.

AGMB performance versus SPY

Price and return data through 2026-10-16.

Total return is -48.3% over the past 0.7 years, 61.8 points behind SPY at 13.5%.

AGMB key facts

Asset type

Stock

Asset class

Equity

Inception date

02/05/2026

Distribution frequency

None

Last close

$8.28 (as of 2026-10-16)

Market cap

$407,773,233

Average volume

78132.0

Payout ratio

0.0%

EPS

$-2.08

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AGMB risks and drawbacks

Total return has trailed SPY over the available window.

Who may consider AGMB — and who may not

It is a weaker fit for investors who need monthly cash flow (AGMB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AGMB

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions